Similarly, A2AR antagonists confer neuroprotection in animal models of stroke, Parkinson’s disease, Alzheimer’s disease and traumatic brain injury, most likely by controlling neuroinflammation, excitotoxic neuronal damage and synaptopathy [18]. This evidence concerns the gene ADORA2A and early-onset autosomal dominant Alzheimer disease.